Introduction
============

Bladder cancer (BC) is the seventh-most common malignancy and the second-most common urological malignancy in men [@B1]. It was reported that annually, the number of new BC cases were more than 79,000, and annual death cases led by BC were more than 16,000 [@B2]. Patients with metastatic BC generally have a poor prognosis, surviving just a few months because of the ease with which it invades the muscle layer [@B3]. In previous studies, approximately 10-15% of BC patients were reported to present at diagnosis with metastatic disease [@B4],[@B5]. Bone metastases (BM) were reported to be correlated with skeletal complications and decrease survival and quality of life in urogenital neoplasms patients [@B6]-[@B8].

It is widely accepted that early diagnosis of BM from BC could benefit from timely medical intervention and skeletal-related events (SREs) prevention [@B4],[@B7]. Currently, there are no screening guidelines for performance of routine evaluation of BM in BC patients. Clinically, diagnosis of BM in BC patients mainly relies on bone scan and PET-CT scanning. However, considering the high cost burden of these tests, neither bone scan nor PET-CT can be used as routine screening strategies. Additionally, it was reported that tumour markers in BC are not sensitive enough to predict BM [@B9]. Thus, studies looking into risk factors for BM in BC are warranted.

A new study based on 902 patients with BC suggested the incidence of BM is 5.5% [@B5]. That study also concluded that concentrations of alkaline phosphatase (ALP) \>116 U/L, HB \<37.5 g/L and calcium \>2.54 mmol/L were the main risk factors that led patients with BC to develop BM [@B5]. However, to build an accurate and portable BM-preventive system for BC, knowledge of additional common clinical risk factors was needed. Accordingly, to further summarize the epidemiological characteristics and prognosis of metastatic BC and to find more risk factors for BM, the present study was performed.

National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) is an open access database that provides cancer incidence and survival data from 18 established cancer registries across the United States, comprising approximately 30% of the total US population. SEER cohort is a widely used database, with complete demographic and clinical data and long-term, high quality follow-up for assessing cancer epidemiological characteristics around the world.

The SEER database was employed in the present study. The incidence and risk factors for BM with initial BC were analysed. Meanwhile, for BC patients presenting with BM at diagnosis, survival estimates and prognostic factors were summarized.

Methods
=======

Patients diagnosed with bladder cancer were selected from the SEER programme between 2010 and 2014, because sites of metastases were not collected until 2010. The datasets generated and/or analysed during the current study are available in the SEER database. (Information Management Service, Inc. Calverton, MD, USA, <https://seer.cancer.gov/data/>). Data on the primary site labelled "bladder cancer (C67.0-67.9)" was identified. The exclusion criteria were as follows: patients \<18 years old (adult\'s patients); diagnosed with carcinoma in situ and benign; diagnosed at autopsy or via death certificate; unknown BM or follow-up. To identify BM risk factors, 87,750 patients within the SEER database diagnosed with BC with definite details about BM from January 1, 2010, to December 31, 2014, were selected. Among those, for survival analysis, 963 BC patients with BM who were initially diagnosed between 2010 and 2013 were retrieved. (Figure [1](#F1){ref-type="fig"})

Ethnics Statement
-----------------

The SEER database is an open public database, and the release of data from the SEER database does not require informed patient consent because cancer is a reportable disease in every state of the United States. The present study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statistical analysis
--------------------

To determine the risk factors for developing BM at diagnosis, univariate and multivariate logistic regression were performed. Patients\' clinical data were collected: age (≤40, 41-60, 61-80 and ≥81 years), sex (female and male), race \[white, black, AI (American Indian/Alaska Native), and API (Asian or Pacific Islander)\], marital status (married and unmarried), insurance status (insured and uninsured), primary tumor (T) stage (T1, T2, T3, and T4), regional lymph node stage (N0, N1, N2 and N3), tumor differentiation grade (grade I, grade II, grade III, and grade IV), the presence or absence of lung metastases, liver metastases, or brain metastases. The primary goal of the survival analysis was to determine overall survival, defined as the time from diagnosis of BC to all causes of death. Survival rate was calculated using the Kaplan-Meier method, and the difference between survival curves was tested by log-rank test. At the same time, based on these factors, combined with the factor of surgical treatment of primary site (none or yes), a multivariable Cox proportional hazards regression was utilized to investigate the associations with overall survival among BC patients with BM.

All the data were obtained using SEER\*Stat Software version 8.3.5. All statistical analyses were performed using SPSS 23.0 (IBM Corporation, Armonk, NY), and all charts of survival were prepared by MedCalc 15.2.2. Two-sided *P* values less than 0.05 were considered as statistically significant.

Results
=======

Incidence of bone metastases
----------------------------

Based on the setting criteria, a total of 87,750 eligible patients were diagnosed with BC between 2010 and 2014; BM was found in 1.39% (1,223/87,750) of the entire cohort at initial diagnosis. In the cohort, 963 BC patients with BM were followed up for more than 1 year. (Table [1](#T1){ref-type="table"})

Risk factors for developing bone metastases
-------------------------------------------

Univariate analysis showed that factors significantly associated with BM occurrence included: older age (OR=0.86, 95% CI: 0.80-0.94, *P*\<0.001), race (OR=1.15, 95% CI: 1.06-1.24, *P*\<0.001), marital status (OR=0.61, 95% CI: 0.55-0.69, *P*\<0.001), insured status (OR=0.48, 95% CI: 0.35-0.66, *P*\<0.001), higher primary tumor (T) stage (OR=2.68, 95% CI: 2.55-2.83, *P*\<0.001), higher regional lymph node (N) stage (OR=3.24, 95% CI: 3.04-3.45, *P*\<0.001), poor tumor differentiated grade (OR=2.09, 95% CI: 1.92-2.28, *P*\<0.001), the presence of lung metastases (OR=44.51, 95% CI: 38.47-51.49, *P*\<0.001), liver metastases (OR=51.11, 95% CI: 43.51-60.03, *P*\<0.001), or brain metastases (OR=53.68, 95% CI: 35.83-80.41, *P*\<0.001).

As shown in Table [1](#T1){ref-type="table"}, multivariate logistic regression suggested that factors significantly associated with BM at initial diagnosis included: age between 41 to 60 years (OR=0.87, 95% CI: 0.77-0.98, *P*=0.03), black race (OR=1.12, 95% CI: 1.00-1.26, *P*=0.046), unmarried status (OR=0.83, 95% CI: 0.70-0.98, *P*=0.03), higher T stage (OR=1.66, 95% CI: 1.53-1.81, *P*\<0.001), higher N stage (OR=1.62, 95% CI: 1.47-1.79, *P*\<0.001), poor tumor differentiated grade (OR=1.72, 95% CI: 1.53-1.93, *P*\<0.001), and the presence of lung metastases (OR=9.87, 95% CI: 7.71-12.63,*P*\<0.001), liver metastases (OR=10.63, 95% CI: 7.98-14.17, *P*\<0.001), or brain metastases (OR=7.73, 95% CI: 3.45-17.31, *P*\<0.001).

Survival and prognostic factors for BM
--------------------------------------

Once BC patients were diagnosed with BM, their survival rates were dramatically decreased. The overall 1-year survival of the cohort was 84% but it was only 21% among patients with BM. The median overall survival time for 963 BC patients with BM was only 4 months (95% CI: 3.55-4.45 months, Figure [2](#F2){ref-type="fig"}A), and 915 (95.02%) patients died at the end of follow-up. In the univariate analysis model, factors including older age (Figure [2](#F2){ref-type="fig"}B), American Indian/Alaska Native race (Figure [2](#F2){ref-type="fig"}C), and the presence of lung metastases (Figure [2](#F2){ref-type="fig"}D), liver metastases (Figure [2](#F2){ref-type="fig"}E), or brain metastases (Figure [2](#F2){ref-type="fig"}F) were negatively associated with overall survival. Conversely, surgical treatment of the primary site was found to be positively associated with overall survival rate (*P*\<0.001, Figure [2](#F2){ref-type="fig"}G).

In the multivariate stepwise Cox regression model (Table [2](#T2){ref-type="table"}), elder (HR=1.31, 95% CI: 1.18-1.45, *P*\<0.001), the presence of lung metastases (HR=1.19, 95% CI: 1.02-1.40, *P*=0.03), liver metastases (HR=1.53, 95% CI: 1.30-1.81, *P*\<0.001), or brain metastases (HR=1.47, 95% CI: 1.04-2.09, *P*=0.03) were negatively associated with overall survival; however, surgery was positively associated with overall survival (HR=0.83, 95% CI: 0.77-0.89, *P*\<0.001).

Discussion
==========

It was reported that approximately 5% of the BC patients presented initially with metastatic disease, with bone being the second-most affected organ and it was reported to occur in 30% to 40% patients with metastatic BC [@B10],[@B11]. With the largest population known to date, this study looked into the incidence of BC patients with BM at diagnosis and showed 1.39% of the entire BC cohort was identified with BM at diagnosis.

The identification of the risk factors for BM development in BC patients makes it possible to guide physicians in the management of the high-risk patient of developing metastasis, increase the quality of life and decrease skeletal related events. Based on our risk factors analysis, we determined that BC patients are likely being diagnosed with BM, when they present with a series of factors, including age between 41 to 60 years, black race, unmarried marital status, higher T stage, higher N stage, poor tumor grade, and the presence of lung, liver, and brain metastases, which was in line with other urinary system cancers [@B12]-[@B14]. Accordingly, the examinations such as bone scan may be considered as an optional method for the patients with the aforementioned factors for BM development.

Additionally, black race was proved to be one of the risk factors for BM at diagnosis, which was consistent with other reported cancer types [@B13],[@B15],[@B16]. Previous studies also reported black patients showed higher-stage disease and worse disease-specific survival compared with white patients [@B17],[@B18]. Further studies looking into the potential explanations for black patients\' poor survival in metastatic tumor and the access to care, quality of care and treatment plans for black BC patients with BM is warranted.

In the present study, BC patients who presented with BM at diagnosis showed a marked decrease in survival rates compared with BC patients without BM occurrence, the median OS for the BM cohort was only 4 months. In the previous study, the 5-year cancer-specific survival following a diagnosis of metastatic BC was reported to be only 8% [@B19]. Our results further proved the poor survival of BC patients with BM at diagnosis. The latest study suggested that among the three most common genitourinary neoplasms, compared with median survival times for patients with BM in prostate cancer (210 days) and kidney cancer (182 days), survival for bladder cancer (68 days) was the worst [@B20]. Based on our prognostic factors analysis, we clarified that BC patients with BM at diagnosis were associated with a significantly higher risk of mortality when they presented with a series of factors, including advanced age, absence of surgery, and presence of lung metastases, liver metastases, and brain metastases. The effect of metastatic sites on patients\' prognosis among several neoplasms was studied [@B21],[@B22]. Liver metastases, bone metastases, and brain metastases have been proven to be independent unfavourable prognostic factors for BC patients [@B23].

To our knowledge, our study is the first to analyse prognostic factors for BC patients with BM. Physicians should pay more attention to their patients\' presentation with the revealed factors. Early supportive treatment and intimate observation should be considered for these patients. Targeted treatment strategies and medical care should be paid on the BC patients with high risk factors for death, to prolong the survival time and implement the tertiary prevention. Further research should be performed to find more prognostic factors to build an accurate predictive system for BC patients with BM.

The major limitation of the present study came from the SEER database itself, as the real BM rate in BC patients might be underestimated for nonrecording in asymptomatic cases. In addition, information on skeletal-related events, thought to be one of the most important prognostic factors in urologic malignancies, were not available. Additionally, the present study was performed based on the SEER cohort and the results were not validated by external dataset. More related studies were needed to further confirm the results in the future to validate the extrapolation of results.

The incidence of BM in newly diagnosed BC patients was approximately 1.39%. BM dramatically decreased the survival of BC patients. Bone scan should be considered a routine examination for BC patients of black race at initial diagnosis. The risk and prognostic factors for BC patients with BM identified herein may provide the basis for early detection of BM in BC patients, and guide clinicians to choose targeted treatment options to promote their survival.
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###### 

Multivariate logistic regression for analysing demographic and related clinical characteristics for developing Bone Metastases in patients with initial bladder cancer (diagnosed 2010-2014).

  ------------------------------------------------------------------------------------------------------------------
  Subject characteristics   Patients\' No. of BC (2010-2014)   OR (95% CI)   P-value                       
  ------------------------- ---------------------------------- ------------- --------- ------------------- ---------
  **Age, in years**                                                                    0.87(0.77-0.98)     0.03

  ≤40                       10                                 890           1.12      1(Reference)        1.00

  41-60                     257                                14533         1.77      1.93(0.58-6.40)     0.28

  60-80                     677                                49908         1.36      1.51(0.46-4.97)     0.50

  ≥81                       279                                22419         1.24      1.25(0.38-4.17)     0.71

  **Race**                                                                             1.12(1.00-1.26)     0.046

  White                     1036                               77512         1.34      1(Reference)        1.00

  Black                     121                                5124          2.36      1.55(1.18-2.02)     0.001

  AI                        7                                  280           2.5       0.78(0.22-2.78)     0.70

  API                       58                                 3540          1.64      1.25(0.83-1.86)     0.29

  Unknown                   1                                  1294          0.08      NA                  NA

  **Marital Status**                                                                                       

  Unmarried                 569                                29594         1.92      1(Reference)        1.00

  Married                   598                                50544         1.18      0.83(0.70-0.98)     0.03

  Unknown                   56                                 7612          0.74      NA                  NA

  **Insurance**\                                                                                           
  **Status**                                                                                               

  Insured                   1181                               86249         1.37      1(Reference)        1.00

  Uninsured                 42                                 1501          2.79      1.20(0.67-2.17)     0.54

  **T Stage**                                                                          1.66(1.53-1.81)     \<0.001

  T1                        187                                66564         0.28      1(Reference)        1.00

  T2                        457                                12627         3.62      5.56(4.40-7.01)     \<0.001

  T3                        90                                 3499          2.57      2.58(1.81-3.66)     \<0.001

  T4                        209                                2902          7.20      6.31(4.69-8.50)     \<0.001

  Unknown                   280                                2158          12.97     NA                  NA

  **N Stage**                                                                          1.62(1.47-1.79)     \<0.001

  N0                        663                                82425         0.81      1(Reference)        1.00

  N1                        101                                1451          6.96      1.64(1.19-2.28)     0.003

  N2                        190                                1840          10.33     2.85(2.22-3.66)     \<0.001

  N3                        56                                 436           12.84     4.38(2.97-6.46)     \<0.001

  Unknown                   213                                1598          13.33     NA                  NA

  **Grade**                                                                            1.72(1.53-1.93)     \<0.001

  I                         11                                 9687          0.11      1(Reference)        1.00

  II                        38                                 15262         0.25      1.54(0.69-3.45)     0.30

  III                       261                                12531         2.08      4.71(2.27-9.78)     \<0.001

  IV                        544                                27124         2.01      4.95(2.41-10.16)    \<0.001

  Unknown                   369                                23146         1.59      NA                  NA

  **Lung Met**                                                                                             

  None                      846                                86551         0.98      1(Reference)        1.00

  Yes                       332                                1086          30.57     9.87(7.71-12.63)    \<0.001

  Unknown                   45                                 113           39.82     NA                  NA

  **Liver Met**                                                                                            

  None                      917                                86912         1.06      1(Reference)        1.00

  Yes                       274                                776           35.31     10.63(7.98-14.17)   \<0.001

  Unknown                   32                                 62            51.61     NA                  NA

  **Brain Met**                                                                                            

  None                      1139                               87590         1.30      1(Reference)        1.00

  Yes                       41                                 99            41.41     7.73(3.45-17.31)    \<0.001

  Unknown                   43                                 61            70.49     NA                  NA
  ------------------------------------------------------------------------------------------------------------------

Abbreviations: BC, bladder cancer; AI, American Indian/Alaska Native; API, Asian or Pacific Islander; Met, metastases; NA, not available; OR, odds ratio; CI, confident interval. All factors with Unknown Data were removed from Multivariable Logistic Regression model.

###### 

Multivariable Cox Regression for analysing prognostic factors for primary bladder cancer with bone metastases (diagnosed 2010-2013).

  -------------------------------------------------------------------------------------------------------------------------
  Subject characteristics   Patients\' No. of\   Survival, Median (95% CI), mo   HR (95% CI)    P-Value           
                            BC with BM                                                                            
  ------------------------- -------------------- ------------------------------- -------------- ----------------- ---------
  **Age, in years**                                                                             1.31(1.18-1.45)   \<0.001

  ≤40                       8                    8(100.00)                       4(0.00-8.16)   1(Reference)      1.00

  41-60                     201                  186(92.54)                      5(3.74-6.26)   0.83(0.40-1.69)   0.60

  61-80                     537                  505(94.04)                      4(3.36-4.64)   0.97(0.48-1.97)   0.94

  ≥81                       217                  216(99.54)                      2(1.50-2.50)   1.46(0.71-2.98)   0.30

  **Race**                                                                                      1.08(0.98-1.18)   0.13

  White                     817                  776(94.98)                      4(3.50-4.50)   1(Reference)      1.00

  Black                     95                   90(94.74)                       4(3.18-4.82)   1.09(0.87-1.37)   0.44

  AI                        6                    6(100.00)                       0(NR)          3.50(1.45-8.49)   0.01

  API                       45                   43(95.56)                       3(0.62-5.39)   1.20(0.88-1.64)   0.25

  **Lung Met**                                                                                                    

  None                      670                  633(94.48)                      4(3.46-4.54)   1(Reference)      1.00

  Yes                       257                  248(96.50)                      3(2.47-3.53)   1.19(1.02-1.40)   0.03

  Unknown                   36                   34(94.44)                       NR             NA                NA

  **Liver Met**                                                                                                   

  None                      721                  678(94.04)                      4(3.51-4.49)   1(Reference)      1.00

  Yes                       218                  214(98.17)                      2(1.54-2.46)   1.53(1.30-1.81)   \<0.001

  Unknown                   24                   23(95.83)                       NR             NA                NA

  **Brain Met**                                                                                                   

  None                      893                  847(94.85)                      4(3.54-4.46)   1(Reference)      1.00

  Yes                       34                   34(100.00)                      2(1.47-2.54)   1.47(1.04-2.09)   0.03

  Unknown                   36                   34(94.44)                       NR             NA                NA

  **Surg(pri)**                                                                                                   

  None                      303                  296(97.69)                      2(1.46-2.54)   1(Reference)      1.00

  Yes                       658                  617(93.77)                      5(4.37-5.63)   0.83(0.77-0.89)   \<0.001

  Unknown                   2                    2(100)                          NR             NA                NA
  -------------------------------------------------------------------------------------------------------------------------

Abbreviations: BC, bladder cancer; BM, bone metastases; AI, American Indian/Alaska Native; API, Asian or Pacific Islander; Met, metastases; Surg(pri), surgical treatments of primary site; NR, not reached; NA, not available; HR, hazard ratio; CI, confident interval. All factors with Unknown Data were removed from multivariable Cox regression model and Kaplan-Meier analysis.
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